EMulate Therapeutics Inc. Announces Publication of Pre-Clinical Mouse Model Demonstrating Direct Evidence of Immune Checkpoint Receptor Knock-Down in a Mouse Glioblastoma Model

On August 20, 2024 EMulate Therapeutics, Inc. ("Emulate") reported the Open Journal of Biophysics (OJBIPHY), publisher of over 200 peer-reviewed open access journals, has accepted its manuscript, titled "Magnetic Field Emulations of Small Inhibitor RNA: Effects on Implanted GL261 Tumors in C57BL/6 Immune Competent Mice" for publication (Press release, EMulate Therapeutics, AUG 20, 2024, View Source [SID1234646020]). This submission supports independent results in an animal model of Glioblastoma Multiforme (GBM), recently published by Mukthavaram et al. (Bioelectron Med 2024 Vol. 10 Issue 1 Pages 10), which demonstrates the ability of EMulate’s second signal treatment offering, A2. GBM is a rare brain glioma that currently has no established treatment on the market and is categorized by the U.S. Food and Drug Administration (FDA) as a highly underserved orphan disease (affects fewer than 200,000 in the U.S.). View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The paper demonstrates EMulate’s A2 signal treatment targets the established immune checkpoint inhibitor targets of CTLA-4 and PD-1, reducing the expression of these immune system receptors and inhibiting the growth of tumors in a validated mouse model of GBM. These results support the observed outcomes from a Phase I clinical trial (NCT02507102) demonstrating safety and possible efficacy against GBM in humans.

"The results of this pre-clinical animal model study continue to demonstrate the potential of our ulRFE technology in the treatment of cancers and other challenging diseases with high unmet medical needs. We strongly believe in the potential benefits of this treatment in patients afflicted by cancer with these genetic targets, which we intend to confirm in future clinical trials," stated Xavier Figueroa, Ph.D., EMulate’s SVP of Pre-Clinical Development.